{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:37:02Z","timestamp":1760647022581},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Doravirine is a novel nonnucleoside reverse transcriptase inhibitor indicated for the treatment of HIV type 1 infection. A subset of people living with HIV receives methadone for the treatment of opioid addiction. The current study (NCT02715700) was an open\u2010label, multiple\u2010dose, drug interaction study in participants on a methadone maintenance program to investigate potential drug\u2010drug interactions between doravirine and methadone. Participants received a stable methadone maintenance dose of 20 to 180 mg once daily for 14 days prior to day 1 and remained on their maintenance dose over days 1 through 7. On days 2 through 6, an oral dose of doravirine 100 mg was coadministered. For doravirine and methadone pharmacokinetic analysis, blood samples were collected before dosing through 24 hours after dosing. Fourteen participants were enrolled; all participants completed the study. For <jats:italic>R<\/jats:italic>\u2010methadone, geometric least squares mean ratios (90% confidence intervals) for dose\u2010normalized area under the plasma concentration\u2013time curve from time zero to 24 hours, plasma concentration at 24 hours, and maximum plasma concentration ([methadone + doravirine]\/methadone alone) were 0.95 (0.90\u20101.01), 0.95 (0.88\u20101.03), and 0.98 (0.93\u20101.03), respectively. For doravirine, based on a comparison with historical data, modest decreases in area under the plasma concentration\u2013time curve from time zero to 24 hours, plasma concentration at 24 hours, and maximum plasma concentration were observed after coadministration of doravirine and methadone; geometric least squares mean ratios ([methadone + doravirine]\/doravirine alone [90% confidence intervals]) were 0.74 (0.61\u20100.90), 0.80 (0.63\u20101.03), and 0.76 (0.63\u20100.91), respectively. Coadministration of doravirine and methadone was generally well tolerated. No serious adverse events occurred, and there were no discontinuations. In conclusion, coadministration of methadone and doravirine did not have a clinically meaningful effect on the pharmacokinetic profile of either agent.<\/jats:p>","DOI":"10.1002\/cpdd.699","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:08:44Z","timestamp":1558606124000},"page":"151-161","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone"],"prefix":"10.1002","volume":"9","author":[{"given":"Sauzanne","family":"Khalilieh","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka L.","family":"Yee","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa I.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Vaynshteyn","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Searle","sequence":"additional","affiliation":[{"name":"PRA Health Sciences  Raleigh NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Bouhajib","sequence":"additional","affiliation":[{"name":"Pharma Medica Research Inc.  Mississauga ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Kenilworth NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance Report \u2010 Diagnoses of HIV Infection in the United States and Dependent Areas 2016.https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-report-2016-vol-28.pdf. Published 2016. Accessed January 23 2019."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301162"},{"key":"e_1_2_10_4_1","unstructured":"American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use.https:\/\/www.asam.org\/docs\/default-source\/practice-support\/guidelines-and-consensus-docs\/asam-national-practice-guideline-supplement.pdf. Published2015. Accessed January 23 2019."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v19n01_07"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.13.18"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03374.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000167043"},{"key":"e_1_2_10_9_1","unstructured":"United Nations Office on Drugs and Crime (UNODC). Methadone Maintenance Treatment.https:\/\/www.unodc.org\/documents\/southasia\/Trainingmanuals\/Methadone_Low_res_09-06-12.pdf. Published2012. Accessed January 23 2019."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.t01-1-00591.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/J354v19n04_05"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.137"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059419"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199606000-00001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19532"},{"issue":"4","key":"e_1_2_10_18_1","first-page":"TUAB0104","article-title":"Efficacy and safety of doravirine 100 mg QD vs efavirenz 600 mg QD with TDF\/FTC in ART\u2010naive HIV\u2010infected patients: week 24 results","volume":"18","author":"Gatell JM","year":"2015","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0458-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01364-16"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02016-18"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02491-18"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02492-18"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2920"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02502-18"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1103"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01757-16"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0513-4"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533558"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200007010-00008"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2009.00005.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199808150-00004"},{"issue":"6","key":"e_1_2_10_34_1","first-page":"619","article-title":"Pharmacokinetic interactions of zidovudine and methadone in intravenous drug\u2010using patients with HIV infection","volume":"5","author":"Schwartz EL","year":"1992","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04389.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:24:44Z","timestamp":1694168684000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/cpdd.699"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.699","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"2019-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}